OCGN Stock: Why The Price Increased Today

By Amit Chowdhry ● Oct 20, 2021
  • The stock price of Ocugen, Inc. (NASDAQ: OCGN) increased by over 5% pre-market today. This is why it happened.

The stock price of Ocugen, Inc. (NASDAQ: OCGN) – a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19 – increased by over 5% pre-market today. Investors are responding positively to Ocugen announcing that its head of Research and Development, Arun Upadhyay, PhD, will present pre-clinical data demonstrating how the company’s second modifier gene therapy candidate OCU410 could potentially be an effective therapeutic for Dry Age-related Macular Degeneration (Dry AMD).

The presentation at the 2nd Annual Dry AMD Therapeutic Development conference will highlight how the use of a specific nuclear hormone receptor called RORA presents a unique opportunity to treat people with Dry AMD. Dry AMD accounts for 85% to 90% of all cases of age-related macular degeneration, which is estimated to be about 196 million people globally. 

RORA plays a central role in many physiological activities, including lipid metabolism, oxidative stress, regulation of Th17 cells (which are involved in many immune-mediated diseases), the reduction of inflammation, and obesity. And in the presentation “OCU410: A Novel Modifier Gene Therapy Product using a Multi-Factor Approach for Dry AMD,” Dr. Upadhyay will show evidence highlighting how influencing the RORA receptor can attack several underlying factors of this serious blindness disease. And Dr. Upadhyay is going to be speaking on October 20, 2021, at 3:15 pm Eastern Time.

OCU410 is the second drug candidate from Ocugen’s Modifier Gene Therapy Platform – which is expected to enter clinical trials in 2022. And Ocugen recently announced a collaboration with CanSinoBIO for the chemistry, manufacturing, and controls (CMC) development and manufacture of clinical supplies of OCU410 to advance the program. 

Modifier Gene Therapy is different from traditional gene augmentation. Instead of replacing a defective gene, a modifier gene like the nuclear hormone receptor RORA regulates cellular and genetic activities just like how a conductor directs an orchestra.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.